Abstract
Background: Epidemiological studies show that BCG-vaccinated population seems to be more likely protected from COVID-19 infection, but WHO gave a stark warning on use of BCG vaccine without confirmed COVID-19 trials. The aim of the study is to evaluate whether TB vaccination, performed several years earlier, could confer protection against COVID-19. Methods: After the Ethical Committee authorization, professional orders were used to contact physicians with an online survey. Specialty, COVID-19 infection and previous BCG vaccination were recorded. Statistical data analysis was performed. Results: 1906 physicians answered the questionnaire, (M = 1068; F = 838; mean age 50.7 ± 13.3 years; range 24–87), more than half (1062; 55.7%) experienced BCG vaccination. Professional activity was recorded, and only 49 subjects (2.6%) of them were infected by SARS-CoV2. Among the group of infected people, asymptomatic form occurred in 12 subjects (24.5%); a pauci-symptomatic form in 24 subjects (49.0%); and a severe form (pneumonia and/or respiratory distress) in 13 (26.5%). Considering only the clinically relevant form of COVID-19, period prevalence was 2.2% (23/1062) in the vaccinated group and 1.7% (14/844) in the unvaccinated group (OR: 1.31, 95% C.I.: 0.68–2.63, p = 0.427). Conclusion: Our experience does not confirm the possible protective role of BCG vaccination, performed years earlier, against COVID-19. Although recent epidemiological studies point out in BCG-vaccinated population a lower prevalence of SARS-CoV2 infection, in our cohort of physicians no significant difference was found in terms of prevalence of COVID-19 infection. Our data underline the necessity to follow the WHO warning about the indiscriminate use of BCG vaccine, until clear evidence of protection by BCG vaccination against COVID-19 is fully demonstrated.
Highlights
At the end of December 2019, the Chinese authorities informed the World Health Organization (WHO) of a series of pneumonialike cases in the city of Wuhan, likely originating from a fish and animal market in the city (Li et al, 2020)
In January 2020, the first news about the viral outbreak detected in the city of Wuhan was confirmed by the Chinese government, about a new virus belonging to the coronavirus family (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020)
It is well known that Bacillus Calmette–Guérin (BCG) vaccine protects against serious tuberculosis disease for up to 15 years after vaccination, while in some cases is more effective than it was thought, offering protection for at least 20 years (Mangtani et al, 2018)
Summary
At the end of December 2019, the Chinese authorities informed the World Health Organization (WHO) of a series of pneumonialike cases in the city of Wuhan, likely originating from a fish and animal market in the city (Li et al, 2020). Bacillus Calmette–Guérin (BCG), a live attenuated strain of Mycobacterium bovis, was originally developed by Albert Calmette and Camille Guérin at the beginning of the 20th century, with the aim to prevent tuberculosis (TB) (Calmette et al, 1927). Epidemiological studies show that BCG-vaccinated population seems to be more likely protected from COVID-19 infection, but WHO gave a stark warning on use of BCG vaccine without confirmed COVID-19 trials. The aim of the study is to evaluate whether TB vaccination, performed several years earlier, could confer protection against COVID-19
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
